

July 2003

CURRICULUM VITAE

I. PERSONAL

A. Name: Jonathan Andrew Tobert

B. Home Address: _____

C. Home Telephone: _____

II. EDUCATION

<u>School</u>	<u>Date</u>	<u>Major/Minor Courses</u>	<u>Degree</u>
Trinity College, University of Cambridge England	1967	Natural Sciences	B.A.
The Middlesex Hospital, University of London England	1970	Medicine	M.B., B. Chir, (equivalent to U.S. M.D. degree)
The School of Pharmacy University of London England	1975	Pharmacology	Ph.D.

III. MERCK/MRL EMPLOYMENT HISTORY

Title _____ From - To _____

Executive Director, Scientific Staff
Clinical Research
Endocrinology and Metabolism

Executive Director November 1988 - 1991
Clinical Research
Endocrinology and Metabolism

III. MERCK/MRL EMPLOYMENT HISTORY (cont'd.)

Senior Director Clinical Research Endocrinology and Metabolism	1986 - 1988
Senior Physician Clinical Research Endocrinology and Metabolism	1982 - 1986
Director Clinical Pharmacology Int'l	1979 - 1982
Associate Director Clinical Pharmacology Int'l	1976 - 1979

IV. NON-MERCK EMPLOYMENT HISTORY

N/A

V. ACADEMIC EXPERIENCE

- A. Internship in Obstetrics and Gynecology at the Middlesex Hospital, London, England, 1970-71.
- B. Internship in Internal Medicine at the Ipswich Hospital, Suffolk, England, 1971.
- C. Teaching Fellowship in Pharmacology at the School of Pharmacy, University of London, 1971-75.
- D. Research Fellowship in Biological Chemistry in the Laboratory of Human Reproduction and Reproductive Biology, Harvard Medical School, Boston, MA, 1975-76.

VI. SOCIETY MEMBERSHIPS

Council of Arteriosclerosis, American Heart Association

VII. ACADEMIC AND PROFESSIONAL HONORS

Lalor Foundation Postdoctoral Fellowship, 1975-76
Merck Directors' Scientific Award, 1989

VIII. PATENTS AND PUBLICATIONS

PATENTS

J.A. Tobert (1980). Rapid acting combination of phenylbenzoic acid compounds and magnesium hydroxide. U.S. Patent No. 4,217,340, 8/12/80.

E.H. Blaine, E.J. Cragoe, Jr., R.F. Hirschmann, J.F. Nancarrow, J.A. Tobert (1985). Indacrinone having enhanced uricosuric properties. U.S. Patent No. 4,520,322, 4/9/85.

J.A. Tobert (1990). Coenzyme Q₁₀ with HMG-CoA reductase inhibitors. U.S. Patent No. 4,929,437, 5/29/90.

PUBLICATIONS

Papers

J.A. Tobert, J.D.H. Slater, F. Fogelman, S.L. Lightman, A.B. Kurtz, and N.N. Payne (1973). The effect in man of (+)-propranolol and racemic propranolol on renin secretion stimulated by orthostatic stress. Clinical Science, 44, 291-295.

J.A. Tobert (1975). The effect of hormonal state on the dissolution of copper in the rabbit uterus. Contraception, 10, 203-210.

J.A. Tobert (1975). Induction of deciduomata by intrauterine copper in the rabbit. Journal of Reproduction and Fertility, 45, 197-200.

J.A. Tobert (1976). A nonsurgical method for the instillation of fluids into the rat uterine lumen and its use to study the possible role of prostaglandins in decidualization. Journal of Reproduction and Fertility, 47, 391-393.

J.A. Tobert and D.R. Davies (1977). The effects of copper and platinum interuterine devices on endometrial morphology and implantation in the rabbit. Journal of Reproduction and Fertility, 50, 53-59.

D.J. Talley, J.A. Tobert, E.G. Armstrong, and C.A. Villee (1977). Changes in progesterone and receptor levels during deciduoma development in the pseudopregnant rat. Endocrinology, 101, 1538-1544.

- E.G. Armstrong, J.A. Tobert, D.J. Talley, and C.A. Villee (1977). Changes in progesterone receptor levels during deciduomata development in the pseudopregnant rat. Endocrinology, 101, 1545-1551.
- M.B. Affrime, D.T. Lowenthal, J.A. Tobert, J. Shirk, B. Eidelson, T. Cook, and G. Onesti (1980). Dynamics and kinetics of ophthalmic timolol. Clinical Pharmacology and Therapeutics, 27, 471-477.
- P.J. Ravenscroft, G.R. Hall, J.T. Ahokas, B.T. Emmerson, and J.A. Tobert (1980). Indacrinone: modification of diuretic, uricosuric and kaliuretic actions by amiloride. Clinical Pharmacology and Therapeutics, 29, 45-51.
- J.A. Tobert, V.J. Cirillo, G. Hitzenberger, I.M. James, J.S. Pryor, T. Cook, A. Buntinx, I.B. Holmes, and P.M. Lutterbeck (1981). Enhancement of the uricosuric properties of indacrinone by manipulation of the enantiomer ratio. Clinical Pharmacology and Therapeutics, 29, 344-350.
- J.A. Tobert, P. DeSchepper, T.B. Tjandramaga, A. Mullie, M.A.P. Meisinger, A. Buntinx, P.B. Huber, and T.L.P. Hall (1981). The effect of antacids on the bioavailability of diflunisal in the fasting and postprandial states. Clinical Pharmacology and Therapeutics, 30, 385-389.
- J.A. Tobert, G. Hitzenberger, W.R. Kukovetz, I.B. Holmes, and K.H. Jones (1982). Rapid and substantial lowering of human serum cholesterol by mevinolin (MK-803), an inhibitor of hydroxymethylglutaryl-coenzyme A reductase. Atherosclerosis, 41, 61-65.
- J.A. Tobert, G.D. Bell, J. Birtwell, I. James, W.R. Kukovetz, J.S. Pryor, A. Buntinx, I.B. Holmes, Y-S Chao, and J.A. Bolognese (1982). Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, in healthy volunteers. Journal of Clinical Investigation, 69, 913-919.
- E.H. Blaine, G.M. Fanelli, J.D. Irvin, J.A. Tobert, and R.O. Davies (1982). Enantiomers of indacrinone: a new approach to producing an isouricemic diuretic. Clinical and Experimental Hypertension, A4 (1-2), 161-176.
- T.S. Parker, D.J. McNamara, C.D. Brown, R. Kolb, E.H. Ahrens, Jr., A.W. Alberts, J.A. Tobert, J. Chen, and P.J. DeSchepper (1984). Plasma mevalonate as a measure of cholesterol synthesis in man. Journal of Clinical Investigation, 74, 795-804.
- W.B. Abrams, J.D. Irvin, J.A. Tobert, R.K. Ferguson, and P.H. Vlasses (1985). Enantiomers of indacrinone. New Drugs Annual: Cardiovascular Drugs, 3, 1-20. Ed. A. Scriabine, Raven Press, New York.

D.A. Henry, K.W. Somerville, G.K. Kitchingman, I.B. Holmes, J.A. Tobert, and M.J.S. Langman (1985). L-643.441: an H₂-receptor antagonist with potent and long-lasting effects in man. British Journal of Clinical Pharmacology, 20, 133-136.

I. Gottesman, J.A. Tobert, R. Vandlen, and J. Gerich (1986). Efficacy, pharmacokinetics and tolerability of a somatostatin analogue (L-363.586) in insulin-dependent diabetes mellitus. Life Sciences, 38, 2211-2219.

D.B. Hunninghake, V.T. Miller, R.H. Palmer, G. Schonfeld, E.A. Stein, J.A. Tobert, J.A. Bolognese, A.C. Goldberg, G.E. Lamkin, J.C. LaRosa, A.S. Leon, M. Adams, C. Anderson, M. Swenson, I.J. Goldberg, M.J. Mellies, P.A. Rhymer, and D.B. Stoy (1986). Therapeutic response to lovastatin (mevinolin) in non-familial hypercholesterolemia. A multicenter study. JAMA, 256, 2829-2834.

J.A. Tobert (1987). New developments in lipid-lowering therapy: the role of inhibitors of HMG-CoA reductase. Circulation, 76, 534-538.

R.J. Havel, D.B. Hunninghake, D.R. Illingworth, R.S. Lees, E.A. Stein, J.A. Tobert, S. Bacon, J.A. Bolognese, P. Frost, G. Lamkin, A. Lees, A. Leon, K. Gardner, G. Johnson, M. Mellies, P.A. Rhymer, P. Tun (1987). Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study. Annals of Internal Medicine, 107, 609-615.

J.F. Walker, J.A. Tobert (1988). Lovastatin and simvastatin: an overview. Atherosclerosis Reviews, 18, 189-193.

Lovastatin Study Group III (1988). A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia. Journal of the American Medical Association, 260, 359-366.

J.A. Tobert (1988). Efficacy and long-term adverse effect pattern of lovastatin. The American Journal of Cardiology, 62, 28J-34J.

A.W. Alberts, J.S. MacDonald, A.E. Till, and J.A. Tobert (1989). Lovastatin. Cardiovascular Drug Reviews, 7, 89-109.

R.J. Havel, J. Davignon, C.A. Dujovne, R. Gregg, D.B. Hunninghake, T. Miettinen, U. Steinbrecher, J.A. Tobert (1989). AHA Conference Report on Cholesterol Workshop VI. Drug Therapy. Circulation, 80, 744-748.

J.A. Tobert, C.L. Shear, A.N. Chremos, G.E. Mantell (1990). Clinical experience with lovastatin. The American Journal of Cardiology, 65, 23F-26F.

Lovastatin Study Group IV (1990). A multicenter comparison of lovastatin and probucol in the treatment of severe primary hypercholesterolemia. The American Journal of Cardiology, 66, 22B-30B.

- J.A. Tobert (1991). The HMG-CoA reductase inhibitors - similarities and differences. European Review for Medical & Pharmacological Sciences, XIII, 25-33.
- J.A. Tobert (1991). The HMG-CoA reductase inhibitors - similarities and differences. Current Drugs: Anti-Atherosclerotic Agents, B21-B29.
- J.A. Tobert for Lovastatin Study Groups I, II, III, and IV (1993). Lovastatin five-year safety and efficacy study. Archives of Internal Medicine, 153, 1079-1087.
- D.B. Hunninghake, E.A. Stein, C.A. Dujovne, W.S. Harris, E.B. Feldman, V.T. Miller, J.A. Tobert, P.M. Laskarzewski, E. Quiter, J. Held, A.M. Taylor, S. Hopper, S.B. Leonard, B.K. Brewer (1993). The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia. New England Journal of Medicine, 328, 1213-1219.
- D.R. Illingworth, J.A. Tobert (1994). A review of clinical trials comparing HMG-CoA reductase inhibitors. Clinical Therapeutics, 16, 366-385.
- D.R. Illingworth, E.A. Stein, R.H. Knopp, D.B. Hunninghake, M.H. Davidson, C.A. Dujovne, V.T. Miller, P.M. Laskarzewski, J.A. Tobert, A.C. Tate (1996). A Randomized multicenter trial comparing the efficacy of simvastatin and fluvastatin. Journal of Cardiovascular Pharmacology and Therapeutics, 1(1), 23-30.
- T.R. Pedersen, J.A. Tobert (1996). Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal. Drug Safety, (1), 11-24.
- E.A. Stein, M. Davidson, C.A. Dujovne, D.B. Hunninghake, R.B. Goldberg, D.R. Illingworth, R.H. Knopp, V.T. Miller, P.H. Frost, Y.B. Mitchel, M.R. Melino, J.A. Cheng, J.A. Tobert (1996). Efficacy and tolerability of low-dose simvastatin and niacin, alone and in combination, in patients with combined hyperlipidemia: A prospective trial. The Journal of Cardiovascular Pharmacology and Therapeutics, 1(2), 107-116.
- J. Kjekshus, T.R. Pedersen, J.A. Tobert (1996). Lipid-lowering therapy for patients with or at risk of coronary artery disease. Current Opinion in Cardiology, 11, 418-427.
- T.R. Pedersen, K. Berg, T.J. Cook, O. Færgeman, T. Haghfelt, J. Kjekshus, T. Miettinen, T.A. Musliner, A.G. Olsson, K. Pyörälä, G. Thorgeirsson, J.A. Tobert, H. Wedel, L. Wilhelmsen (1996). Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Archives of Internal Medicine, 156, 2085-2092.
- M.H. Davidson, E.A. Stein, C.A. Dujovne, D.B. Hunninghake, S.R. Weiss, R.H. Knopp, D.R. Illingworth, Y.B. Mitchel, M.R. Melino, R.V. Zupkis, M.R. Dobrinska, R.D. Amin, J.A. Tobert (1997). The efficacy and six-week tolerability of simvastatin 80 and 160 mg day. American Journal of Cardiology, 79, 38-42.

T.R. Pedersen, J. Kjekshus, K. Pyörälä, A.G. Olsson, T.J. Cook, T.A. Musliner, J.A. Tobert, T. Haghfelt (1998). Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). American Journal of Cardiology, 81, 333-335.

T.R. Pedersen, A.G. Olsson, O. Færgeman, J. Kjekshus, H. Wedel, K. Berg, L. Wilhelmsen, T. Haghfelt, G. Thorgeirsson, K. Pyörälä, T. Miettinen, B. Christoperson, J.A. Tobert, T.A. Musliner, T.J. Cook, for the Scandinavian Simvastatin Survival Group (1998). Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation, 97, 1453-1460.

J.R. Crouse III, J. Frohlich, L. Ose, M. Mercuri, J. A. Tobert (1999). Effects of High Doses of *Simvastatin* and *Atorvastatin* on High-Density Lipoprotein Cholesterol and Apolipoprotein A-I. American Journal of Cardiology, 83(10), 1476-1477.

P.J.K. Gruer, J.M. Vega, M.F. Mercuri, M.R. Dobrinska, J.A. Tobert (1999). Concomitant use of cytochrome p450 3A4 inhibitors and simvastatin. American Journal of Cardiology, 84, 811-815.

M. MacMahon, C. Kirkpatrick, C.E. Cummings, A. Clayton, P.J. Robinson, R.H.H. Tomiak, M. Liu, D. Kush, J.A. Tobert (2000). A pilot study with simvastatin and folic acid/vitamin B₁₂ in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH). Nutrition, Metabolism, and Cardiovascular Diseases, 10, 195-203.

J.A. Tobert, D.R. Illingworth (2001). HMG-CoA reductase inhibitors. Drug Discovery and Design for Advances in Protein Chemistry, 56, 77-114, Ed. Dr. E. M. Scolnick. Academic Press, San Diego, California.

J.A. Tobert (2003). Lovastatin and Beyond: The history of the HMG-CoA reductase inhibitors. Nature Reviews – Drug Discovery, 2, 517-526.

Letters

Lovastatin Study Group II (1987). Inhibitors of cholesterol synthesis and cataracts. JAMA, 257, 1602.

J.A. Tobert (1988). Myopathy during therapy with lovastatin. NEJM, 318, 48.

D.B. Hunninghake, V.L. Miller, I. Goldberg, G. Schonfeld, E.A. Stein, J.A. Tobert (1988). Lovastatin: follow-up ophthalmologic data. JAMA, 259, 354-355.

- J.A. Tobert (1988). HMG-CoA reductase inhibitors for hypercholesterolemia. NEJM, 319, 1222-1223.
- J.A. Tobert for the Lovastatin Study Group III (1988). Lovastatin vs. cholestyramine therapy for primary hypercholesterolemia. JAMA, 260, 3590-3591.
- G.J. Gormley, J.A. Tobert (1989). Drug interaction between thyroxine and lovastatin. NEJM, 321, 1341-1342.
- J.A. Tobert (1990). The cholesterol myth. The Atlantic, 13-14.
- T.S. Bocanegra, J.A. Tobert (1990). Lipid lowering drugs. BMJ, 300, 1195.
- J.A. Tobert (1991). Cholesterol lowering and non-cardiac mortality. The Lancet, 338, 126.
- J.A. Tobert (1992). The cholesterol controversy. British Medical Journal, 304, 713.
- S.P. Spielberg, J.A. Tobert (1992). HMG-CoA reductase inhibitors and sleep. Clinical Pharmacology and Therapeutics, 52, 109-110.
- G.A. Block, Y.B. Mitchel, J.A. Tobert, D.R. Shapiro (1992). Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance. Clin Cardiol, 15, A24-790.
- J.A. Tobert (1993). Relative safety and efficacy of pravastatin. Clinical Pharmacy, 12, 256-257.
- J.A. Tobert (1993). Blood cholesterol measurement in young adults. JAMA, 270, 936.
- J.A. Tobert (1994). Lovastatin and Myopathy. Amer J Med, 94, 301.
- J.A. Tobert (1994). HMG-CoA reductase inhibitors, gemfibrozil, and myopathy. Amer J Cardiol.
- J.A. Tobert, G.A. Block (1995). Lovastatin-associated sleep and mood disturbances. Amer J Med, 99, 108-109.
- J.A. Tobert (1996). Statin therapy and CHD. The Lancet, 347, 128.
- J.A. Tobert (1996). Comment on paper by Newman and Hulley. JAMA, 275(19), 1480-1481.
- J.A. Tobert, A.V. Katdare (1997). Efficacy and tolerability of fluvastatin and simvastatin in hypercholesterolaemic patients. Clinical Drug Investigation, 13(1), 56-57.

J.A. Tobert, J.M. Vega, M. Dobrinska, P.J.K. Gruer (1999). Calcium channel blocker-simvastatin interaction. Clinical Pharmacology & Therapeutics, 65(5), 583.

P.J.K. Gruer, J. Vega, M.F. Mercuri, M.R. Dobrinska, J.A. Tobert (2000). Reply to letter from Bottorff to the editor. American Journal of Cardiology, 85(8), 1043.

**APPEARS THIS WAY
ON ORIGINAL**